Prosecution Insights
Last updated: October 26, 2026
Application No. 18/700,668

BIS-AMINOPHOSPHINES AS CATALYSTS FOR THE DIMERIZATION OF ALKYL ACRYLATES

Non-Final OA §102§112
Filed
Apr 11, 2024
Priority
Oct 18, 2021 — EU 21203095.1 +1 more
Examiner
MCCAIG, BRIAN A
Art Unit
1772
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Speciality Operations France
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1091 granted / 1356 resolved
+15.5% vs TC avg
Moderate +13% lift
Without
With
+13.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
17 currently pending
Career history
1383
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
43.0%
+3.0% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
31.5%
-8.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1356 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status This Office action is based on the 18/700,668 application filed 11 April 2024, which is being examined under the first inventor to file provisions of the AIA . Claims 1-15 are pending and have been fully considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 recites “…reacting the compound according to formula (III) as obtained at step a) with an amine…” There is no “step a)” in the claim or any preceding claim. Therefore, the metes and bounds of the claimed invention cannot be determined. Additionally, claim 6 recites “…the steps a) and b) are performed in an organic solvent…” Again, there are no “steps a) and b)” in claim 5. See, also, “step b)” in instant claim 7. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-4 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Virieux et al in Science of Synthesis (2009, “42.12 Alkylphosphonium Salts,” pp 503-594). With respect to claims 1-4, Virieux et al discloses “synthesis of aminophosphonium salts 209, by phosphorus alkylation of an aminophosphine, is a more amenable process. Due to the high nucleophilic character of such reagents, the reaction generally proceeds smoothly at room temperature. Aminophosphonium salts are more stable than the previous heterophosphonium salts” [see last paragraph on page 577]. PNG media_image1.png 153 436 media_image1.png Greyscale Note that the aminophosphine compound on the left hand side, (Ph)P(R1)(NR2R3), when R1 is NMe2 or pyrrolidine-1-yl and NR2R3 is N-iPr2, corresponds to formula (I) in instant claim 1 wherein R1,R2 are C1 alkyl or pyrrolidinyl and R3 is an aryl (phenyl) group. When R1 is pyrrolidinyl, said group is a heteroaliphatic cycle comprising 4 carbon atoms in which the heteroatom is N. Allowable Subject Matter Claims 8-15 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: the prior art does not teach the use of the compound of formula (I) as a catalyst for dimerization of an alkyl acrylate. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN A MCCAIG whose telephone number is (571)270-5548. The examiner can normally be reached Monday to Friday 8 to 4:30 Mountain Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, In Suk Bullock can be reached at 571-272-5954. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN A MCCAIG/Primary Examiner, Art Unit 1772 30 September 2026
Read full office action

Prosecution Timeline

Apr 11, 2024
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766498
PLATFORM FOR THE RECOVERY OF TRANSITION METAL CATALYSTS
3y 8m to grant Granted Oct 20, 2026
Patent 12758954
CATALYST SYSTEM AND PROCESS FOR PRODUCING BISPHENOL-A
3y 5m to grant Granted Oct 13, 2026
Patent 12758953
HYDROISOMERIZATION CATALYSTS
3y 3m to grant Granted Oct 13, 2026
Patent 12758910
CATALYTICALLY ACTIVE PARTICULATE FILTER BODY AND METHOD OF MAKING
3y 2m to grant Granted Oct 13, 2026
Patent 12758958
Immobilization of Molecular Catalysts on Solid Powders via Vapor Deposition of Encapsulating Nano-Layers for Use as Heterogeneous Chemical Catalysts
3y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
94%
With Interview (+13.3%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1356 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month